Lenz Therapeutics (NASDAQ:LENZ), a biotechnology company developing eye drops for presbyopia, released its second quarter 2025 results on July 30, 2025. The most striking news: Lenz recognized $5.0 million in GAAP revenue from licensing milestones, stunning analysts who expected just $0.71 million (GAAP). At $0.53 GAAP EPS compared to a $0.61 consensus loss. Despite ramped up spending that pushed the net loss (GAAP) deeper than the prior year, the company executed strongly on its commercial readiness plans ahead of a key FDA decision for its lead product in August. Overall, the quarter was marked by aggressive investments and one-time licensing revenue, setting the stage for the company’s next pivotal phase. Source: Analyst estimates for the quarter provided by FactSet. Lenz Therapeutics is a clinical-stage biotech aiming to reshape vision correction for presbyopia, an age-related loss of near vision affecting people over forty. Its lead product, LNZ100, is a once-daily, preservative-free eye drop designed to temporarily improve near vision without affecting distance vision.Continue readinghttps://www.fool.com/data-news/2025/07/31/lenz-lenz-q2-revenue-jumps-604/
No jobs report again. But these numbers show how the U.S. economy is doing.
November 1, 2025
Investors are set to miss out on the second U.S. jobs report in a row due to the government shutdown, but there’s enough scattered evidence to suggest the economy is hanging in there.
